Biologics have revolutionized the treatment of many chronic autoimmune conditions

The value they provide to patients is significant. Although subsequent entry biologics (SEBs) may be priced lower, should patients be switched for non-medical reasons simply to save money?
This article examines the market for biologics in an era of SEBs, seeking to better understand savings, risks of non-medical switching, and the patient support plan sponsors and employees can expect.